辉瑞与Valneva SE今日共同公布,其合作研发的莱姆病候选疫苗在关键性3期VALOR临床试验中取得了显著的疗效数据。该试验结果证实,疫苗在预防莱姆病方面表现出强有力的保护作用,标志着这一备受关注的传染病预防项目取得重要进展。
辉瑞与Valneva SE今日共同公布,其合作研发的莱姆病候选疫苗在关键性3期VALOR临床试验中取得了显著的疗效数据。该试验结果证实,疫苗在预防莱姆病方面表现出强有力的保护作用,标志着这一备受关注的传染病预防项目取得重要进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.